Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis.

ABSTRACT: Inhibitors targeting Abl kinase have dramatically improved survival in Philadelphia chromosome-positive leukemias. First-generation imatinib has minimal cardiovascular side effects, whereas newer agents such as dasatinib, ponatinib, and nilotinib are more effective cancer treatments but carry a high risk of arterial thrombosis. The allosteric Abl kinase inhibitor asciminib was recently approved without long-term cardiovascular follow-up. Previous studies reveal disparate effects of dasatinib, ponatinib, and nilotinib on platelets with consistent evidence of endothelial cell (EC) toxicity. Here, we explore prothrombotic endothelial toxicity mechanisms by comparing exposure to vehicle vs clinically relevant concentrations of imatinib, dasatinib, ponatinib, nilotinib, and asciminib on primary

SUBMITTER: Travers R 

PROVIDER: S-EPMC12820586 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature